Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 2/20 | 0.36 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.36 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.36 |
| ▸ | GCK | P35557 | 3/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1062732 | 0.84 | MAPK14 (0.34) | CACNA1GCACNA1HCACNA1IGCKTMEM97 | |
| SCHEMBL1061639 | 0.84 | CACNA1G (0.36) | CACNA1GCACNA1HCACNA1IGCKMAPK14 | |
| SCHEMBL1064925 | 0.84 | CACNA1G (0.33) | CACNA1GCACNA1HCACNA1ITMEM97SIGMAR1 | |
| SCHEMBL1063050 | 0.83 | GCK (0.34) | CACNA1GCACNA1HCACNA1IGCK | |
| SCHEMBL1062231 | 0.83 | CASP1 (0.33) | CACNA1GCACNA1HCACNA1IGCKTMEM97 | |
| SCHEMBL1063252 | 0.82 | P2RX3 (0.33) | CACNA1GCACNA1HCACNA1IGCKMAPK14 | |
| SCHEMBL1083004 | 0.82 | TMEM97 (0.31) | CACNA1GCACNA1HCACNA1IGCKTMEM97 | |
| SCHEMBL1063173 | 0.82 | CASP1 (0.35) | CACNA1GCACNA1HCACNA1I | |
| SCHEMBL1062681 | 0.81 | CCNK (0.33) | CACNA1GCACNA1HCACNA1IGCK | |
| SCHEMBL1064938 | 0.80 | CACNA1G (0.35) | CACNA1GCACNA1HCACNA1IMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258134-B2 | Pyridazinone glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2012-09-04 | — | — | US | disclosed |
| EP-2268633-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | F. Hoffmann-La Roche AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| US-20090264434-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2009-10-22 | — | — | US | disclosed |
| WO-2009127544-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264434-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | GCK, GCKR, PDXK | CACNA1G 4277/4885CACNA1H 4512/4885CACNA1I 3922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.